Bharat Parenterals gets DCGI nod for Favipiravir oral suspension

Drug firm Bharat Parenterals on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for favipiravir oral suspension, to be used for treatment of Covid-19 patients.

The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parenterals said in a regulatory filing.

Favipiravir, an antiviral drug, was approved in Japan in 2014 for the treatment of novel or re-emerging influenza virus infections.

Related Posts

National Pharmaceutical Pricing Authority notifies retail price of 42 new drugs

New Delhi:  The National Pharmaceutical Pricing Authority (NPPA) has notified retail price of 42 new drugs under the provisions of the Drugs Prices Control Order (DPCO), 2013, including anti hypertensive,…

World’s First Malaria Treatment for Newborns and Young Infants Receives WHO Prequalification

New Delhi– In a landmark development for global child health, the World Health Organization (WHO) has granted prequalification to Coartem® Baby (artemether-lumefantrine), the first and only antimalarial medicine specifically developed…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

A SSi Mantra fame Robotic Telesurgery Champion pulls off another Spectacular Intercontinental

A SSi Mantra fame Robotic Telesurgery Champion pulls off another Spectacular Intercontinental

National Pharmaceutical Pricing Authority notifies retail price of 42 new drugs

National Pharmaceutical Pricing Authority notifies retail price of 42 new drugs

World’s First Malaria Treatment for Newborns and Young Infants Receives WHO Prequalification

World’s First Malaria Treatment for Newborns and Young Infants Receives WHO Prequalification

FIR Lodged Against Pharmacist in Chandauli for Working Nearly 10 Years on Forged Documents

FIR Lodged Against Pharmacist in Chandauli for Working Nearly 10 Years on Forged Documents

Laughing all the Way to Health with Sir Ganga Ram Hospital

Laughing all the Way to Health with Sir Ganga Ram Hospital

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson